A Registry Study of Biomarkers in Heart Failure

A Registry Study of Biomarkers in Heart Failure

The registry study aims to discover the prognostic value of bio-markers in heart failure

The purpose of this study is to investigate the prognostic value of biomarkers in Heart Failure.Patients with confirmed diagnosis of heart failure are enrolled.The primary outcome is all-cause mortality based on the death certificates. The secondary outcome is readmission for heart failure and all-cause mortality/readmission for heart failure according to the patients' medical records.

Inclusion Criteria:

• Age greater than or equal to 18 years at the time of admission to the hospital
• With symptoms of new-onset or worsening heart failure
• Received or is eligible to receive a principal hospital discharge diagnosis of HF
• With signs and syndromes as follows: dyspnea at rest or with minimal exertion (dyspnea, orthopnea, or edema)；Rales, peripheral edema, ascites, or pulmonary vascular congestion on chest radiography.
• Patients who received packed red blood cells, whole blood, or platelets less than 10 days before the blood sample was taken;

Exclusion Criteria:

• Have objective evidence of cardiac dysfunction documented either by plasma concentrations of BNP and/or N-terminal pro-brain natriuretic peptide (NT-proBNP) <35 pg/mL or <125 pg/ml, respectively
• Current known inability to follow instructions or comply with follow-up procedures.
• Eligible patients without informed consent form